Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.32 |
| ▸ | SPR | P35270 | 3/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26306182 | 0.89 | PLAT (0.32) | IRAK4SPRPLAT | |
| SCHEMBL23948428 | 0.87 | EGLN1 (0.36) | IRAK4HPGDSALKBH2EGLN1SPR | |
| SCHEMBL23948296 | 0.81 | TDO2 (0.41) | IRAK4PLATALDH1A1MAPTHPGD | |
| SCHEMBL23948319 | 0.79 | KCNJ5 (0.33) | IRAK4PLAT | |
| SCHEMBL26309079 | 0.78 | HCAR1 (0.36) | IRAK4EGLN1PLATMAPT | |
| SCHEMBL26306183 | 0.78 | HCAR1 (0.34) | IRAK4PLAT | |
| SCHEMBL23947948 | 0.78 | KDM4A (0.33) | IRAK4 | |
| SCHEMBL26306212 | 0.78 | IRAK4 (0.30) | IRAK4PLAT | |
| SCHEMBL23948425 | 0.77 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL23948301 | 0.77 | PLAT (0.34) | EGLN1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2021211882-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | LTK, FRK, LCK | IRAK4 471/4885HPGDS 2792/4885ALKBH2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.